Allogene Therapeutics ALLO Increase (Decrease) in Deposit Assets
Increase (Decrease) in Deposit Assets at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInDepositOtherAssets.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's increase (decrease) in deposit assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's increase (decrease) in deposit assets?
- Allogene Therapeutics (ALLO) reported increase (decrease) in deposit assets of -$23.48M in Q1 2026.
- How has Allogene Therapeutics's increase (decrease) in deposit assets changed year-over-year?
- Allogene Therapeutics's increase (decrease) in deposit assets decreased by 2805.0% year-over-year, from $868K to -$23.48M.
- What does increase (decrease) in deposit assets mean?
- This reflects changes in cash held as deposits or other non-current assets that are restricted or held for specific contractual purposes. Fluctuations in this balance indicate changes in the company's collateral requirements or long-term security deposits. It provides insight into the liquidity tied up in non-operating assets.